Coiled Therapeutics (COIL) investor relations material

Company overview and leadership

• Recently listed on AIM (London Stock Exchange) with a strong board and management team, including recent additions of experienced non-executive directors and a medical advisory board.

• Focused on a novel oncology target (TAC3) with first-mover advantage and a differentiated approach in the clinic.

• Management has invested significant personal capital and established strategic engagements with major pharmaceutical companies.

Clinical progress and data highlights

• Lead program AO-252 is in phase I dose escalation, showing 80% clinical benefit rate in heavily pretreated patients, with no serious adverse events and strong safety profile.

• Demonstrated brain penetration and efficacy in multiple solid tumors, including ovarian, endometrial, and prostate cancers.

• Early data indicate tumor regression and partial responses, even at sub-maximal doses.

Scientific rationale and differentiation

• TAC3 is a biologically validated, selective tumor dependency, confirmed by independent DepMap analysis.

• The small molecule induces DNA damage and uniquely activates the immune system, converting cold tumors to hot and enabling synergy with immunotherapies.

• Preclinical and clinical data support broad applicability across at least 350,000 patients in the US and Europe, excluding brain metastasis cases.